Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 17, 2024
There
is
growing
recognition
of
the
potential
cannabis
to
treat
various
medical
conditions
and
symptoms,
such
as
chronic
pain,
spasticity,
epilepsy.
However,
one
biggest
challenges
assurance
a
standardized
product
that
contains
consistent
amount
its
main
psychoactive
substances
delta-9-tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
which
compliant
with
predetermined
specifications
for
these
compounds.
This
crucial
not
only
ensure
quality
dosage
patients
but
also
effectively
translate
research
findings
into
clinical
practice.
Addiction,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 13, 2025
Abstract
Background
and
Aims
Substance
use
disorders
(SUD)
lead
to
a
high
burden
of
disease,
yet
treatment
options
are
limited.
Cannabidiol
(CBD)
is
being
investigated
as
potential
therapeutic
target
due
its
pharmacological
properties
mode
action
in
the
endocannabinoid
system.
Recent
systematic
reviews
(SR)
on
CBD
SUDs
have
shown
inconsistent
results.
The
objective
this
umbrella
review
was
determine
whether
alone
or
combination
with
Δ‐9‐tetrahydrocannabinol
(THC)
effective
for
managing
treating
SUDs.
Methods
Following
registered
protocol,
we
searched
PubMed,
Web
Science
Epistemonikos
databases
SRs,
without
meta‐analysis,
randomized
controlled
trials
focusing
interventions
dispensing
CBD,
THC,
treat
SUDs,
published
from
1
January
2000
15
October
2024.
Screening,
data
extraction
quality
assessment
AMSTAR
2
tool
were
performed
by
two
researchers
parallel
duplicated.
Results
22
SRs
included,
5
which
meta‐analysis.
We
found
mixed
evidence
regarding
efficacy
manage
Findings
interpreted
light
SRs.
Nabiximols,
contains
demonstrated
positive
effects
cannabis
withdrawal
craving
symptoms.
Evidence
supporting
limited
inconclusive
abstinence,
reduction
cessation
cannabis,
tobacco,
alcohol,
opiates
other
psychoactive
substances.
Conclusion
monotherapy
does
not
appear
be
efficacious
substance
disorders.
primarily
exhibits
when
combined
(THC).
Existing
regard
outcomes
related
Neuroscience & Biobehavioral Reviews,
Journal Year:
2024,
Volume and Issue:
162, P. 105699 - 105699
Published: May 6, 2024
Robust
epidemiological
evidence
of
risk
and
protective
factors
for
psychosis
is
essential
to
inform
preventive
interventions.
Previous
syntheses
have
classified
these
according
their
strength
association
with
psychosis.
In
this
critical
review
we
appraise
the
distinct
overlapping
mechanisms
25
key
environmental
psychosis,
link
mechanistic
pathways
that
may
contribute
neurochemical
alterations
hypothesised
underlie
psychotic
symptoms.
We
then
discuss
implications
our
findings
future
research,
specifically
considering
interactions
between
factors,
exploring
universal
subgroup-specific
improving
understanding
temporality
dynamics,
standardising
operationalisation
measurement
developing
interventions
targeting
factors.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(3), P. 319 - 319
Published: March 1, 2025
Cannabis
is
the
most
commonly
used
illicit
substance
worldwide.
Recent
years
have
seen
an
increase
in
cannabis
consumption,
and
with
new
approvals
therapeutic
indications,
there
are
challenges
minimizing
risks
interactions
between
cannabis-based
products,
prescription
drugs,
other
approved
substances
of
abuse.
Thus,
identifying
enzymes
metabolizing
cannabinoid
drugs
their
relationship
crucial
for
understanding
potential
effects
simultaneous
use.
This
article
offers
a
comprehensive
review
pharmacokinetic
as
well
It
also
compiles
existing
evidence
these
describes
clinical
outcomes
associated
inhibition
or
induction
various
enzymes.
Addiction,
Journal Year:
2023,
Volume and Issue:
118(7), P. 1282 - 1294
Published: Feb. 8, 2023
Long-term
harms
of
cannabis
may
be
exacerbated
in
adolescence,
but
little
is
known
about
the
acute
effects
adolescents.
We
aimed
to
(i)
compare
adolescent
and
adult
users
(ii)
determine
if
cannabidiol
(CBD)
acutely
modulates
delta-9-tetrahydocannabinol
(THC).Randomised,
double-blind,
placebo-controlled,
crossover
experiment.
The
experiment
was
registered
on
ClinicalTrials.gov
(NCT04851392).Laboratory
London,
United
Kingdom.Twenty-four
adolescents
(12
women,
16-
17-year-olds)
24
adults
26-
29-year-olds)
who
used
0.5-3
days/week
were
matched
use
frequency
(mean
=
1.5
days/week).We
administered
three
weight-adjusted
vaporised
flower
preparations:
'THC'
(8
mg
THC
for
75
kg
person);
'THC
+
CBD'
CBD
'PLA'
(matched
placebo).Primary
outcomes
subjective
'feel
drug
effect';
verbal
episodic
memory
(delayed
prose
recall);
(iii)
psychotomimetic
effect
(Psychotomimetic
States
Inventory).Compared
with
'PLA',
significantly
(P
<
0.001)
increased
effect'
difference
[MD]
6.3,
95%
CI
5.3-7.2;
MD
6.8,
6.0-7.7),
impaired
(MD
-2.7,
-4.1
-1.4;
-2.9,
-1.7)
7.8,
2.8-12.7;
10.8,
6.2-15.4).
There
no
evidence
that
differed
from
their
responses
(interaction
P
≥
0.4).
Bayesian
analyses
supported
equivalent
(Bayes
factor
[BF01
]
>3).
modulated
THC.Adolescent
are
neither
more
resilient
nor
vulnerable
than
psychotomimetic,
memory-impairing
or
cannabis.
Furthermore,
adults,
does
not
mitigate
caused
by
delta-9-tetrahydocannabinol.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(7), P. 2119 - 2119
Published: April 1, 2023
The
application
of
cannabis
products
in
oncology
receives
interest,
especially
from
patients.
Despite
the
plethora
research
data
available,
added
value
curative
or
palliative
cancer
care
and
possible
risks
involved
are
insufficiently
proven
therefore
a
matter
debate.
We
aim
to
give
recommendation
on
position
clinical
by
assessing
recent
literature.
Various
types
products,
characteristics,
quality
pharmacology
discussed.
Standardisation
is
essential
for
reliable
reproducible
quality.
oromucosal/sublingual
route
administration
preferred
over
inhalation
drinking
tea.
Cannabinoids
may
inhibit
efflux
transporters
drug-metabolising
enzymes,
possibly
inducing
pharmacokinetic
interactions
with
anticancer
drugs
being
substrates
these
proteins.
This
enhance
cytostatic
effect
and/or
drug-related
adverse
effects.
Reversely,
it
enable
dose
reduction.
Similar
likely
used
symptom
management
treating
pain,
nausea,
vomiting
anorexia.
Cannabis
usually
well
tolerated
improve
life
patients
(although
not
unambiguously
proven).
combination
immunotherapy
seems
undesirable
because
immunosuppressive
action
cannabinoids.
Further
warranted
scientifically
support
(refraining
from)
using
cancer.
Neuropsychopharmacology,
Journal Year:
2024,
Volume and Issue:
49(10), P. 1640 - 1651
Published: May 28, 2024
Abstract
Adolescence
is
a
time
of
rapid
neurodevelopment
and
the
endocannabinoid
system
particularly
prone
to
change
during
this
time.
Cannabis
commonly
used
drug
with
high
prevalence
use
among
adolescents.
The
two
predominant
phytocannabinoids
are
Delta-9-tetrahydrocannabinol
(THC)
cannabidiol
(CBD),
which
affect
system.
It
unknown
whether
period
development
makes
adolescents
more
or
less
vulnerable
effects
cannabis
on
brain-network
connectivity,
CBD
may
attenuate
THC.
Using
fMRI,
we
explored
impact
vaporized
(placebo,
THC:
8
mg/75
kg,
THC
+
CBD:
kg
&
24
CBD)
resting-state
networks
in
groups
semi-regular
users
(usage
frequency
between
0.5
3
days/week),
consisting
22
(16–17
years)
young
adults
(26–29
matched
for
frequency.
caused
reductions
within-network
connectivity
default
mode
(F[2,88]
=
3.97,
P
0.022,
η²
0.018),
executive
control
18.62,
<
0.001,
0.123),
salience
12.12,
0.076),
hippocampal
14.65,
0.087),
limbic
striatal
16.19,
0.102)
compared
placebo.
Whole-brain
analysis
showed
significantly
disrupted
functional
cortical
regions
control,
salience,
hippocampal,
did
not
counteract
THC’s
further
reduced
both
within
whole
brain.
While
age-related
differences
were
observed,
there
no
interactions
age
group
treatment
any
brain
network.
Overall,
these
results
challenge
assumption
that
can
make
safer,
as
(and
some
cases
potentiated
them);
furthermore,
they
show
causes
similar
disruption
adolescent
adult
Pain and Therapy,
Journal Year:
2024,
Volume and Issue:
13(5), P. 1063 - 1094
Published: Aug. 3, 2024
Interest
in
medical
cannabis
and
cannabis-based
medicinal
products
(CBMPs)
has
increased
greatly
recent
years.
Two
cannabinoids
are
of
principal
importance;
delta-9-tetrahydrocannabinol
(∆9-THC),
the
primary
psychoactive
component,
also
cannabidiol
(CBD),
considered
non-intoxicating.
Each
distinct
mechanisms
action
different
therapeutic
potentials.
CBMPs
differ
their
∆9-THC
CBD
components;
predominantly
∆9-THC,
balanced
formulations
with
equivalent
elements,
CBD-predominant
products.
In
this
narrative
review,
we
evaluate
published
evidence
for
clinical
benefits
overall
well-being.
We
review
safety
profile
discuss
potential
dependence
CBMPs.
Evidence
can
be
drawn
from
a
wide
range
randomized
other
controlled
studies
observational
real-world
studies.
Most
data
registry
supportive
∆9-THC-based
(∆9-THC-predominant
or
CBMPs)
management
chronic
neuropathic
pain.
Balanced
effective
reducing
spasticity
multiple
sclerosis.
show
benefit
providing
symptomatic
anxiety,
nausea,
improving
sleep,
but
place
specific
is
more
subtle,
choice
guided
by
circumstances.
Symptomatic
improvements
accompanied
improved
quality
life
Safety
indicate
that
generally
well
tolerated
most
patients
without
contraindications.
The
majority
adverse
effects
non-serious,
transient;
principally
associated
dose-dependent.
contrast
to
recreational
use,
there
little
have
any
dependence.
